ROCKVILLE, MD, July 21, 2015  — Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to redefining the management of respiratory disease through innovation, today announced that it has achieved over 50 percent patient enrollment in the second clinical trial evaluating its lead product candidate, CG100, for the prevention of chronic respiratory morbidities, including bronchopulmonary dysplasia (BPD), in premature infants. This phase 2a study is supported in part by a $1.6 M grant from the US FDA Office of Orphan Product Development. For more information, view the press release.